Womenra is a clinically developed prescription medication designed to address hypoactive sexual desire disorder (HSDD) in premenopausal women. It represents a significant advancement in women’s sexual health, offering a non-hormonal, targeted approach to improving libido, arousal, and overall sexual satisfaction. By modulating key neurotransmitters in the brain, Womenra helps restore natural sexual response patterns that may be diminished due to psychological, physiological, or multifactorial causes. This treatment is specifically formulated to work in harmony with the female neuroendocrine system, providing a tailored solution for one of the most prevalent yet under-treated conditions in women’s health care.

Features

• Contains flibanserin 100mg as the active pharmaceutical ingredient
• Non-hormonal mechanism of action targeting serotonin and dopamine receptors
• FDA-approved for premenopausal women with acquired, generalized HSDD
• Once-daily oral tablet formulation for consistent dosing
• Requires prescription and medical supervision throughout treatment
• Clinical trial data demonstrating statistically significant improvement in satisfying sexual events and desire scores

Benefits

• Increases spontaneous and responsive sexual desire through central nervous system modulation
• Enhances overall sexual satisfaction and reduces distress related to sexual dysfunction
• Improves the frequency of satisfying sexual events as demonstrated in controlled clinical trials
• Provides a targeted approach without systemic hormonal effects
• Complements psychological interventions and relationship counseling
• May improve overall quality of life and intimate relationship dynamics

Common use

Womenra is specifically indicated for the treatment of premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD), characterized by persistently or recurrently deficient sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The diagnosis requires that these symptoms not be better accounted for by another medical or psychiatric condition, substance use, or severe relationship discord. It is typically prescribed to women who have experienced a noticeable decline in sexual desire that cannot be attributed to temporary stressors or life circumstances alone. The medication is intended for use as part of a comprehensive approach to sexual health that may include psychological support and relationship counseling.

Dosage and direction

The recommended dosage is one 100mg tablet taken orally once daily at bedtime. Administration at bedtime is crucial due to the potential for sedation, dizziness, and other central nervous system effects. Tablets should be swallowed whole with water and not crushed or chewed. Treatment should be initiated under medical supervision with regular follow-up appointments to assess efficacy and tolerability. The full therapeutic effect may not be apparent until after 8 weeks of continuous dosing, though some women may notice improvements earlier. Dosage adjustments are not recommended; discontinuation should be considered if no meaningful improvement occurs after 8 weeks of treatment. Womenra should not be taken with alcohol or other central nervous system depressants.

Precautions

Patients should be cautioned about the potential for hypotension, syncope, and central nervous system depression, particularly during the initial weeks of treatment. Activities requiring full alertness, including driving or operating machinery, should be avoided until the individual response to the medication is established. Regular monitoring of blood pressure and assessment for sedation is recommended. Womenra should be used with caution in patients with hepatic impairment, and is not recommended for those with severe hepatic insufficiency. Patients should be advised to avoid grapefruit juice during treatment as it may increase flibanserin concentrations. The medication may impair judgment and motor skills; patients should exercise caution when engaging in potentially hazardous activities.

Contraindications

Womenra is contraindicated in patients with known hypersensitivity to flibanserin or any component of the formulation. Concomitant use with moderate or strong CYP3A4 inhibitors is contraindicated due to significantly increased flibanserin exposure. The medication is contraindicated in patients with hepatic impairment (Child-Pugh Class B and C). Concurrent alcohol consumption is absolutely contraindicated due to the risk of severe hypotension and syncope. Womenra should not be used in postmenopausal women or men, as safety and efficacy have not been established in these populations. The medication is also contraindicated in patients with a history of hypotension or those taking antihypertensive medications.

Possible side effects

The most commonly reported adverse reactions include dizziness (11.4%), somnolence (11.2%), nausea (10.4%), fatigue (9.2%), and insomnia (4.9%). These effects are typically dose-related and may decrease in frequency and severity with continued treatment. Less common but potentially serious side effects include syncope (0.4%), hypotension (0.2%), and accidental injury (1.6%). Some patients may experience anxiety, dry mouth, or decreased appetite. The incidence of most adverse events is highest during the first two weeks of treatment and tends to decrease thereafter. Patients should report any persistent or severe side effects to their healthcare provider promptly.

Drug interaction

Womenra undergoes extensive metabolism primarily by CYP3A4 and secondarily by CYP2C19. Concomitant use with moderate or strong CYP3A4 inhibitors (e.g., ketoconazole, fluconazole, erythromycin) is contraindicated. Weak CYP3A4 inhibitors may require increased monitoring. Concurrent use with alcohol significantly increases the risk of hypotension and syncope and is absolutely contraindicated. Caution is advised when co-administering with CNS depressants, including benzodiazepines, opioids, and sedating antihistamines. Womenra may potentiate the effects of other hypotensive agents. The medication may interact with oral contraceptives, though no dosage adjustment is typically required. Healthcare providers should conduct a comprehensive medication review before initiation.

Missed dose

If a dose is missed, patients should skip that dose and take the next scheduled dose at the usual time. Doubling the dose to make up for a missed tablet is not recommended due to the increased risk of adverse effects. Patients should maintain the regular bedtime dosing schedule and should not take more than one tablet within a 24-hour period. If multiple doses are missed, patients should consult their healthcare provider before resuming treatment to determine the appropriate course of action. Consistency in dosing is important for maintaining therapeutic effects while minimizing side effects.

Overdose

In case of suspected overdose, immediate medical attention should be sought. Symptoms may include severe dizziness, profound sedation, hypotension, and syncope. There is no specific antidote for flibanserin overdose. Treatment should be supportive and symptomatic, including monitoring of vital signs and cardiac function. Gastric lavage may be considered if presentation is early after ingestion. Activated charcoal may be administered if the patient presents within one hour of ingestion. Hemodialysis is unlikely to be effective due to high protein binding. Patients should be monitored for at least 24 hours due to the prolonged half-life of the medication.

Storage

Store at room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Tablets should be kept out of reach of children and pets. Do not use if the packaging is damaged or shows signs of tampering. Properly discard any expired or unused medication through medication take-back programs or according to FDA-recommended disposal methods. Do not flush medications down the toilet or pour them into a drain unless specifically instructed to do so.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Womenra is available by prescription only and should be used under the supervision of a qualified healthcare provider. Individual results may vary, and not all patients will experience the described benefits. Patients should discuss their complete medical history, including all medications and supplements, with their healthcare provider before starting treatment. The safety and efficacy of Womenra have been established through clinical trials, but like all medications, it carries potential risks that must be weighed against potential benefits. This information is not exhaustive; patients should refer to the full prescribing information and consult with their healthcare provider for complete guidance.

Reviews

Clinical studies demonstrate that approximately 48-55% of women treated with Womenra experience meaningful improvement in sexual desire and distress scores compared to 30-35% with placebo. Patients reporting positive outcomes frequently describe renewed intimacy in relationships and decreased anxiety about sexual performance. Some women note the medication requires patience, as optimal effects may take 2-3 months to manifest. Healthcare providers emphasize the importance of comprehensive evaluation before prescription, noting that Womenra works best as part of a holistic approach to sexual health that may include counseling and lifestyle modifications. The most common feedback from successful users includes improved spontaneous sexual thoughts and increased responsiveness to sexual cues.